MGI Aloxi approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI Pharma's Aloxi (palonosetron) clears FDA July 25 for prevention of "acute nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic chemotherapy" and "prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy," making it the first 5-HT3 antagonist approved for delayed chemotherapy-induced nausea and vomiting. Marketing efforts will focus on Aloxi's differentiated labeling, superior clinical results and potential pharmacoeconomic benefits. MGI has pointed to the agent's greater affinity for 5-HT3 receptors and longer half-life as key distinguishing factors from GSK's Zofran, Aventis' Anzemet and Roche's Kytril (1Pharmaceutical Approvals Monthly June 1, 2003, p. 7). MGI also notes the potential for use with Merck's substance P antagonist Emend (aprepitant). Aloxi will be priced above the other 5-HT3 agents...
You may also be interested in...
MGI Palonosetron Study Shows Superiority To GSK Zofran; User Fee In July
A pivotal study comparing MGI Pharma’s 5-HT3 antagonist palonosetron to GlaxoSmithKline’s market leader Zofran shows superior efficacy for palonosetron in prevention of chemotherapy-induced nausea and vomiting.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.